ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019
A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments for
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Dual-modality theranostics probes: sintegrative strategies for precision management of oncologic malignancies.Life medicine · 2026Review
- Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations.mAbs · 2025Review
- Reengineered Anti-CD4 Cys-diabody Variants forMolecular imaging and biology · 2025Article
- The Role of Acoustic Parameters in Droplet Vaporization of Perfluoropentane Nanodroplets forACS applied materials & interfaces · 2025Article
- In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions.EJNMMI radiopharmacy and chemistry · 2024Article
- SyntheticRSC medicinal chemistry · 2024Review
- Click Chemistry and Radiochemistry: An Update.Bioconjugate chemistry · 2023Review
- Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer.Cancer letters · 2023Review
- ClickablePharmaceuticals (Basel, Switzerland) · 2022Article
- Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer.Pharmaceutics · 2022Article
- Site-Specific and Residualizing Linker forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Synthesis and ComparativeBioconjugate chemistry · 2021Article
- Contemporary Approaches for Site-Selective Dual Functionalization of Proteins.Angewandte Chemie (International ed. in English) · 2021Review
- Development of anFrontiers in immunology · 2021Article
- Near-infrared fluorescence imaging in immunotherapy.Advanced drug delivery reviews · 2020Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Tri-functional platform for construction of modular antibody fragments forChemical science · 2020Article
- Emerging Fluorescent Molecular Tracers to Guide Intra-Operative Surgical Decision-Making.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Antibody-based dual-modality (PET/fluorescence) imaging enables both presurgery antigen-specific immuno-PET for noninvasive whole-body evaluation and intraoperative fluorescence for visualization of superficial tissue layers for image-guided surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.